Amgen, Inc. (AMGN) Shares Bought by Carret Asset Management LLC

Carret Asset Management LLC grew its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 0.9% during the second quarter, according to its most recent filing with the SEC. The firm owned 5,571 shares of the medical research company’s stock after acquiring an additional 50 shares during the period. Carret Asset Management LLC’s holdings in Amgen were worth $959,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. TrimTabs Asset Management LLC boosted its position in shares of Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after purchasing an additional 288 shares in the last quarter. Jackson Grant Investment Advisers Inc. boosted its position in shares of Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares in the last quarter. American Beacon Advisors Inc. bought a new stake in shares of Amgen in the 1st quarter worth approximately $106,000. Omnia Family Wealth LLC boosted its position in shares of Amgen by 25.3% in the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares in the last quarter. Finally, Grove Bank & Trust boosted its position in shares of Amgen by 87.4% in the 2nd quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after purchasing an additional 341 shares in the last quarter. Hedge funds and other institutional investors own 78.62% of the company’s stock.

Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $176.83 on Tuesday. The firm has a market cap of $127,331.98, a price-to-earnings ratio of 13.94, a price-to-earnings-growth ratio of 2.54 and a beta of 1.36. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. Amgen, Inc. has a 12 month low of $142.79 and a 12 month high of $191.10.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. The firm had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. Amgen’s revenue was down .7% on a year-over-year basis. During the same period in the prior year, the business posted $3.02 EPS. equities research analysts predict that Amgen, Inc. will post 12.66 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 8th. Stockholders of record on Friday, November 17th were paid a $1.15 dividend. The ex-dividend date was Thursday, November 16th. This represents a $4.60 annualized dividend and a dividend yield of 2.60%. Amgen’s dividend payout ratio (DPR) is 41.63%.

Amgen announced that its board has approved a stock repurchase program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Several equities analysts recently issued reports on the company. BMO Capital Markets reaffirmed a “hold” rating and issued a $199.00 price objective on shares of Amgen in a research report on Monday, September 25th. Credit Suisse Group reaffirmed a “neutral” rating and issued a $186.00 price objective (up from $177.00) on shares of Amgen in a research report on Friday, September 29th. BidaskClub raised Amgen from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 2nd. Cann reaffirmed a “buy” rating and issued a $205.00 price objective on shares of Amgen in a research report on Thursday, November 30th. Finally, Mizuho reaffirmed a “buy” rating and issued a $198.00 price objective (up from $183.00) on shares of Amgen in a research report on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $190.22.

In other news, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The disclosure for this sale can be found here. Insiders sold a total of 7,050 shares of company stock valued at $1,239,673 over the last 90 days. 0.19% of the stock is currently owned by company insiders.

WARNING: “Amgen, Inc. (AMGN) Shares Bought by Carret Asset Management LLC” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2017/12/12/amgen-inc-amgn-shares-bought-by-carret-asset-management-llc.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

What are top analysts saying about Amgen Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Amgen Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit